Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
Status:
Completed
Trial end date:
2020-03-20
Target enrollment:
Participant gender:
Summary
The purpose of this Phase I study is to determine the safety and tolerability including the
maximum dose (MTD) and dose-limiting toxicities (DLTs) of alvocidib when administered over a
range of doses on Days 1-3 followed by cytarabine/daunorubicin (7+3) on Days 5-11 in adults
with newly diagnosed and previously untreated AML
Phase:
Phase 1
Details
Lead Sponsor:
Sumitomo Dainippon Pharma Oncology, Inc Tolero Pharmaceuticals, Inc.